Sixty Degree Capital
VC Fund
Toronto, Canada
Sixty Degree Capital is a North American VC that invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO). The firm has a global investment mandate, but currently focuses on the US market.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 0%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sixty Degree Capital invests in
Stages Sixty Degree Capital invests in
Countries Sixty Degree Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 19 (36%)
- Health Care 14 (26%)
- Therapeutics 9 (17%)
- Software 7 (13%)
- Pharmaceutical 7 (13%)
Stage
- Series B 11 (21%)
- Series D 7 (13%)
- Series C 6 (11%)
- Series E 6 (11%)
- Series A 5 (9%)
Country
- United States 29 (55%)
- Canada 2 (4%)
- Germany 2 (4%)
- Switzerland 2 (4%)
- China 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Yatong Li
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Straiker
|
Straiker builds AI-native security solutions tp protect customers from a spectrum of security & safety risks. | $64M / Series A / Jun 29, 2026 | |
Bionyra
|
Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | |
Eclypsium
|
Eclypsium protects organizations from the foundation of their computing infrastructure upward, controlling the risk and stopping threats inside firmware of laptops, servers, and networking infrastructure. | $25M / Series C / Mar 19, 2026 | |
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M / Series B / Mar 18, 2026 | |
HawkEye 360
|
HawkEye 360 is a data analytics company that develops space-based radio frequency mapping. The company operates a commercial satellite constellation to identify, process, and geolocate a broad set of RF signals. Its products include maritime domain awareness and spectrum mapping and monitoring; our customers include a wide range of commercial,government, and international entities.It was founded in 2015 and is headquartered in Herndon, Virginia. | $23M / Series E / Mar 04, 2026 | |
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | |
AAVantgarde Bio
|
AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M / Series B / Nov 03, 2025 | |
Droidrun
|
Droidrun is a cutting-edge software development company that specializes in creating innovative solutions enabling AI agents to seamlessly access and control smartphone applications. By leveraging advanced artificial intelligence and machine learning algorithms, their software facilitates smooth interactions between AI systems and mobile devices,empowering agents to autonomously navigate, operate, and optimize a wide range of apps on both Android and iOS platforms. | $2.5M / Pre-Seed / Jul 23, 2025 | |
Empirical Security
|
Empirical builds mathematical models for security data. | $11.9M / Seed / Jul 17, 2025 | |
| See all 53 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sixty Degree Capital invest in?
Sixty Degree Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series D stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sixty Degree Capital?
Public channels for Sixty Degree Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sixty Degree Capital?
The team at Sixty Degree Capital includes Yatong Li (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
